Iluminos will commercialise compounds with the potential to combat neurodegenerative diseases such as Alzheimer's.
University of Arizona (UA) has established Iluminos Therapeutics, a spinout that will develop compounds to tackle neurodegenerative conditions such as Alzheimer’s disease.
Iluminos was founded with assistance from UA’s tech transfer office, Tech Launch Arizona, to commercialise small molecular-based therapies that inhibit the overproduction of an enzyme called DYRK1A, which has been linked to neurodegenerative conditions.
The approach, which has shown promise tackling Alzheimer’s in pre-clinical trials, builds on research led by Christopher Hulme, professor of medicinal chemistry in UA’s…
